Kedrion Biopharma
Andrea Caricasole has an extensive work experience in the field of neuroscience and drug discovery. Andrea currently holds the position of Chief Research and Innovation Officer at Kedrion Biopharma, a role they have been in since June 2023. Prior to this, they served as the Head of Research and Innovation at the same company starting in October 2019.
Before joining Kedrion Biopharma, Andrea worked at IRBM where they held the role of Senior Director, Neuroscience from an unknown start date until August 2019. Their responsibilities in this role focused on developing therapeutic approaches and biomarkers for neurodegenerative diseases such as Huntington's disease, Parkinson's disease, and Alzheimer's disease.
Andrea also has experience working at the University of Cambridge as the Head of Biology at the Alzheimer's Research UK Cambridge Drug Discovery Institute from March 2016 to December 2016. In this role, they contributed to the discovery of novel therapeutics for Alzheimer's disease and other neurodegenerative diseases.
Prior to their time at the University of Cambridge, Andrea held various positions at IRBM Science Park, including the roles of Senior Director, Neuroscience from October 2014 to February 2016, and Head, Molecular Pharmacology from January 2013 to October 2014. Their work at IRBM involved developing assays and tools to explore mechanisms underlying protein misfolding diseases and studying the toxicity of disease-associated proteins.
Andrea also has experience working at Siena Biotech as the Head of Pharmacology from May 2002 to December 2012. Additionally, they worked as a Senior Molecular Biologist at the University of Rome "La Sapienza" from May 2001 to April 2002, and as a Senior Scientist at GSK from 1999 to 2001.
Furthermore, they have held positions as a Staff Scientist at the Hubrecht Laboratorium, NIOB, KNAW from 1997 to 1998, and as a Post-Doctoral Scientist at both KNAW and the University of Oxford from 1995 to 1997.
Overall, Andrea Caricasole's work experience spans multiple companies and research institutions, with a focus on neuroscience, drug discovery, and neurodegenerative diseases.
Andrea Caricasole received an International Baccalaureate degree in 1986 from the United World College of the Adriatic. They then pursued a B.Sc. in Microbiology from UCL from 1986 to 1989. Finally, they completed their education with a D.Phil. in Molecular Biology from the University of Oxford from 1989 to 1993.
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.